349 results on '"Gomez-Reino, Juan J."'
Search Results
2. Actualización del Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares
3. Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases
4. Efficacy and Safety of Golimumab as Add-on Therapy to Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the GO-MORE Study in Spain
5. Eficacia y seguridad de golimumab añadido a fármacos antirreumáticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en España
6. New drugs from ancient natural foods. Oleocanthal, the natural occurring spicy compound of olive oil: a brief history
7. Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis
8. Adipokines, Molecular Players at the Crossroad Between Inflammation and Oxidative Stress: Role in Arthropathies
9. Predictors of treatment failure and mortality in native septic arthritis
10. Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: An exploratory analysis
11. Further evidence for the anti-inflammatory activity of oleocanthal: Inhibition of MIP-1α and IL-6 in J774 macrophages and in ATDC5 chondrocytes
12. Inmune-mediated inflammatory rheumatic diseases in transgender people: A scoping review
13. Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience
14. THERAPY: The NICE position on indications for biologics and biosimilars
15. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
16. Las adipocinas: mediadores emergentes de la respuesta inmune y de la inflamación
17. Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
18. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies
19. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
20. Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis
21. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
22. Adipokines as novel modulators of lipid metabolism
23. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
24. Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis
25. Adipokines and Systemic Rheumatic Diseases: Linking Inflammation, Immunity and Metabolism
26. Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: An Asian perspective
27. Reply
28. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab
29. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study
30. Association of anti–citrullinated vimentin and anti–citrullinated α-enolase antibodies with subsets of rheumatoid arthritis
31. Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration
32. Particular association of clinical and genetic features with autoimmunity to citrullinated α-enolase in rheumatoid arthritis
33. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0
34. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies
35. Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
36. CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial
37. Ghrelin in the Local Regulation of Endocrine Glands
38. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists
39. Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors
40. Large replication study and meta-analyses of DVWA as an osteoarthritis susceptibility locus in European and Asian populations
41. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
42. A broad analysis of IL1 polymorphism and rheumatoid arthritis
43. Association of Interferon Regulatory Factor 5 Haplotypes, Similar to That Found in Systemic Lupus Erythematosus, in a Large Subgroup of Patients With Rheumatoid Arthritis
44. Genetic variation including nonsynonymous polymorphisms of a major aggrecanase, ADAMTS-5, in susceptibility to osteoarthritis
45. Unlike ghrelin, obestatin does not exert any relevant activity in chondrocytes
46. An SNP in the 5′-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage
47. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
48. Polymorphism of the Interleukin-1 Receptor Antagonist Gene: A Factor in Susceptibility to Rheumatoid Arthritis in a Spanish Population
49. Worsening of obstructive sleep apnoeas in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor
50. Association of PDCD1 With Susceptibility to Systemic Lupus Erythematosus: Evidence of Population-Specific Effects
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.